ニードルフリー(無針)ドラッグデリバリー市場(2014-2024)...市場調査レポートについてご紹介

【英文タイトル】Needle-Free Delivery: Technology and Market Forecast 2014-2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Executive Summary
1.1 Sector Highlights
1.2 Aim, Scope and Format of This Report
1.3 Chapter Outline
1.4 Research and Analysis Methods
1.5 Glossary of Terms Relating to the Report
2. Introduction to Needle-Free Delivery of Drugs/Vaccines
2.1 What is Needle-Free Technology?
2.1.1 History of Needle-Free Injections (NFI)
2.2 Why the Need For Needle-Free Delivery Technology?
2.2.1 Needle Stick Injury
2.2.1.1 Blood-Borne Pathogens and Needle Stick Injury
2.2.1.2 Accidental Needle Stick Injury: A Serious Healthcare Problem
2.3 Clinical Settings Where Needle-Free Delivery Technology Will Be Beneficial
2.3.1 Pain Management
2.3.1.1 Pain Management: Using NFI Devices to Administer Lidocaine
2.3.2 Vaccine Delivery: Improving Immune Response
2.3.2.1 The Global Vaccine Market, 2014-2024
2.3.2.2 Needle-Free Vaccine Delivery
2.3.2.3 Mass Immunisation
2.3.3 Insulin Delivery For Diabetics
2.3.4 Paediatric Injections
2.3.5 Other Uses For Needle-Free Injection Technology
2.4 Advantages and Disadvantages of Needle-Free Injections
2.5 The Needle-Free Delivery Market
2.5.1 Jet Injectors
2.5.1.1 Concerns About Multi-use Nozzle Jet injectors (MUNJIs)
2.5.1.2 Strengths and Weaknesses of Jet Injectors
2.5.2 Competing Needle-Free Technologies
2.5.2.1 Novel Needle Technology
2.5.2.1.1 Pen Needles
2.5.2.1.2 Microneedles
2.5.2.1.3 Hollow Microneedles
2.5.2.1.4 Solid Coated Microneedles
2.5.2.1.5 Solid Biodegradable Microneedles
2.5.2.1.6 Solid Uncoated Microneedles
2.5.2.1.7 Selection of Microneedles
2.5.2.2 Inhaler Technology
2.5.2.3 Transdermal Patch Technology
2.6 Regulation of the Needle-Free Delivery Market
2.6.1 The US Regulation System
2.6.1.1 Combination Products
2.6.1.2 FDA Statement Clamps Down On Delivery of Medications in Non-approved Needle-Free Devices
2.6.2 The European Regulation System
2.6.2.1 Post Marketing Surveillance in the EU
3. The Global Needle-Free Injection Device Market, 2014-2024
3.1 The Needle-Free Delivery Technology Market: Overview
3.2 The Needle-Free Delivery Technology Market by Segments, 2012-2013
3.3 The Needle-Free Delivery Market Forecast, 2014-2024
3.4 Needle-Free Delivery Technology: Market Trends, 2014-2024
4. The Jet Injectors Technology Market, 2014-2024
4.1 The Jet Injectors Market, 2012-2013
4.2 The Jet Injectors Market Forecast, 2014-2024
4.3 Leading Devices in the Jet Injectors Market, 2014
4.3.1 Biojector 2000 (Bioject Medical Technologies)
4.3.2 SUMAVEL DosePro (Zogenix)
4.3.3 E-Jet 100 (Eurojet Medical)
4.3.4 STRATIS (Pharmajet)
4.3.5 ZetaJet (Bioject Medical Technologies)
4.3.6 LectraJet (D’Antonio Consultants International)
4.3.7 Med-Jet (Medical International Technologies)
4.3.8 Vision (Antares Pharma)
4.3.9 Glide System (Glide Pharmaceutical Technologies)
4.3.10 AdvantaJet (Activa Brand Products)
4.3.11 J-Tip (National Medical Products)
4.3.12 SQ-Pen (Diabetes Management International)
4.3.13 Vitajet3 (Bioject Medical Technologies)
4.3.14 Penjet (Penjet Corporation)
4.3.15 INJEX30 (Injex)
4.4 Jet Injectors Development Pipeline, 2014
4.4.1 Zeneo (Crossject Medical Technologies)
4.4.2 Jupiter Jet (Bioject Medical Technologies)
4.4.3 Iject (Bioject Medical Technologies)
4.4.3.1 Iject R (Bioject Medical Technologies)
4.4.4 Relday (Zogenix)
4.5 Concluding Remarks
5. Competing Needle-Free Technology Market, 2014-2024
5.1 Competing Needle-Free Technologies: Overview
5.2 Competing Needle-Free Technology Market, 2012-2013
5.3 Competing Needle Free Technologies Market Forecast by Segments, 2014-2024
5.4 Novel Needle Technology Market, 2013
5.4.1 Novel Needle Technology Market Forecast, 2014-2024
5.4.2 Leading Products in the Microneedle Technology Market, 2014
5.4.3 Microneedle Patches for Vaccine Delivery, 2014
5.4.3.1 Microneedle Patch for the Polio Vaccine (Georgia Tech’s School of
Chemical and Biomolecular Engineering)
5.4.3.2 AdminPen (nanoBioSciences)
5.4.3.3 PKA SoftTouch (PKA SoftTouch Corp)
5.4.3.4 DrugMAT (TheraJect)
5.4.3.5 MicroCor (Corium International)
5.4.3.6 Nanopatch (Vaxxas)
5.4.3.7 ZP Patch Technology (Zosana)
5.5 Inhaler Technology Market, 2013
5.5.1 Inhaler Technology Market Forecast, 2014-2024
5.5.2 Inhalers in the Asthma Market, 2014
5.5.3 Inhalers in the Insulin Market, 2014
5.5.4 Inhalers in the Vaccine Market, 2014
5.6 The Patch Technology Market, 2013
5.6.1 The Patch Technology Market Forecast, 2014-2024
5.6.2 Drug Patches in the Market, 2014
5.7 Other Competing Needle-free delivery Technology in development
5.7.1 Magnetic Injection
5.7.2 Laser Injection
5.7.3 Vaccine Delivery Using Micro-Shock Waves (Indian Institute of Science, Bangalore)
5.7.4 Nanotechnology Syringes (Gwangju Institute of Science and Technology, South
Korea)
5.7.5 Nanotechnology Implant (University of California, San Francisco)
6. Leading National Needle-Free Delivery Markets, 2014-2024
6.1 Leading National Breakdown of the Needle-Free Delivery Market, 2012-2013
6.2 The Leading National Needle-Free Delivery Market Forecast, 2014-2024
6.3 The US Needle-Free Delivery Market Forecast, 2014-2024
6.4 The European Needle-Free Delivery Market, 2013
6.4.1 The European Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.1 The German Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.2 The French Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.3 The Italian Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.4 The Spanish Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.5 The UK Needle-Free Delivery Market Forecast, 2014-2024
6.5 The Japanese Needle-Free Delivery Market Forecast, 2014-2024
6.6 The Chinese Needle-Free Delivery Market Forecast, 2014-2024
6.7 The Indian Needle-Free Delivery Market Forecast, 2014-2024
7. Leading Companies in the Needle-Free Delivery Market 2014
7.1 Antares Pharma
7.1.1 Sales and Performance Analysis
7.1.2 Product Sales, 2012
7.1.3 Revenue by Region, 2012
7.1.4 Revenue by Major Customers, 2011-2012
7.1.5 Sales and Performance Analysis, 3Q 2013
7.1.6 Technology of Antares Pharma
7.1.6.1 Pressure Assisted Injection Devices
7.1.6.2 Transdermal Gel System
7.1.7 Marketed Products, 2014
7.1.8 Pipeline Products, 2014
7.2 Zogenix
7.2.1 Sales and Performance Analysis
7.2.2 Sales by Segment, 2013
7.2.3 Needle-Free Products
7.2.3.1 Marketed Products, 2014
7.2.3.1.1 Sumavel® DosePro®: Rapid Acting Migraine Relief
7.2.3.1.2 Zohydro™ ER (hydrocodone bitartrate) Extended-Release Capsules
7.2.3.1.3 Zohydro™ ER Approval: Cause for Controversy?
7.2.3.1.4 Pipeline Products, 2014
7.2.4 Collaborations
7.2.4.1 Co-promotion of Migranal Nasal Spray with Valeant
7.2.5 Manufacturing
7.3 Bioject Medical Technologies
7.3.1 Sales and Performance Analysis
7.3.2 Sales Performance Analysis by Products
7.3.3 Sales and Performance Analysis, 3Q 2012-2013
7.3.4 Bioject’s Sales Revenue Setbacks
7.3.5 Collaborations
7.3.5.1 Navy Malaria Study: Utilises Bioject’s B2000 Technology
7.3.5.2 Cyto Pulse Sciences: Clinical Trials for an HIV/DNA vaccine
7.3.5.3 CDA intradermal influenza study
7.3.5.4 MPI Research: Seeking Drug/Device Combinations
7.3.5.5 World Health Organisation (WHO): The Push to Eradicate Infectious Disease in Developing Countries
7.3.6 Needle-Free Products
7.3.6.1 Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
7.3.6.2 Vitajet™: Low-cost Insulin Delivery System
7.3.6.3 ZetaJet™: Auto-disable Feature Improves User Safety
7.3.7 Needle-Free Injection Device Pipeline
7.3.7.1 Intradermal Pen Injector: Targeted Drug Delivery
7.3.7.2 Iject®: Providing Tailored Depth of Penetration
7.3.7.3 Jupiter Jet: Multi Dosing With Single Loaded Syringe
7.4 3M
7.4.1 Sales and Performance Analysis
7.4.2 3M Drug Delivery Systems
7.4.2.1 Inhalation
7.4.2.2 Transdermal patch
7.4.2.3 Microneedles
7.5 Medical International Technology (MIT)
7.5.1 Sales and Performance Analysis
7.5.2 Increased Product Awareness Through Globalisation
7.5.2.1 Further Expansion in China
7.5.3 Products
7.5.3.1 Med Jet
7.6 D’Antonio Consultants International (DCI)
7.6.1 Needle-Free Products
7.6.1.1 LectraJet®: Lightweight Device Reduces User Fatigue
7.6.2 Needle-Free Injection Device Pipeline
7.6.2.1 Low Workload Jet Injector: Single-shot Manual System
7.6.2.2 Multi Channel Jet Injector: For Simultaneous Vaccine Delivery
7.7 PharmaJet
7.7.1 Needle-Free Products
7.7.1.1 STRATIS®: Drug Delivery in Less Than a Second
7.7.1.2 Applications
7.7.2 Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
7.8 Akra Dermojet
7.8.1 Needle-Free Products
7.8.1.1 DERMOJET® “HR”: User-Friendly Design Allows Use in High Intensive Applications
7.8.1.2 DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
7.8.1.3 Automatic DERMOJET®
7.9 Injex Pharma
7.9.1 Injex 30
7.9.1.1 Injex 30’s Applications
7.9.2 Injex’s Worldwide Distribution
7.9.2.1 Exclusive Distributor Agreement with Russia’s Medici Ltd.
7.9.2.2 Chinese SFDA approval
7.9.2.3 NHS’s Withdrawal of Injex30
7.10 Glide Pharma
7.10.1 Applications
7.10.1.1 Glide SDI system’s Advantages
7.10.2 Injecting Solid Formulations
7.10.3 Pharmaceutical Companies
7.10.4 Collaboration with Pfenex Inc. to Aid Delivery of Solid Dose Vaccine
8. Qualitative Analysis of the Needle-Free Delivery Market, 2014-2024
8.1 SWOT Analysis of the Needle-Free Delivery Market, 2014-2024
8.2 Strengths
8.2.1 Strong Growth in the Biologic Drug Market
8.2.2 Increasing Development in Transdermal Delivery
8.2.3 No Specialist Training Required for Drug/Vaccine Delivery
8.2.4 Eliminating the Cold Chain Problem
8.2.5 Reduction in Needle Stick Injuries
8.3 Weaknesses
8.3.1 Healthcare Practitioners are not Familiar with Novel Delivery Systems
8.3.2 Current Inefficient Manufacturing Processes Lead to Costly Needle-Free
Technology
8.3.3 Current Technology is Very Expensive
8.4 Opportunities
8.4.1 Emerging Economies Offer Significant Growth Opportunities
8.4.2 Mass Immunisation Programs Around the World
8.4.3 Increasing Global Diabetes Population
8.4.4 Shift Towards Home Administration Setting
8.4.5 Extending Life Cycle of Drugs
8.5 Threats
8.5.1 Traditional Needles and Syringes are Very Cheap to Mass Produce
8.5.1.1 Needle and Syringes with Anti Needle-Stick Injury Technology
8.5.2 Greater Regulatory Scrutiny
8.5.3 Limited Clinical Data
8.5.4 Medical Device Excise Tax
9. Expert Opinion
9.1 Interview with Robert E. Sievers, CEO and President, Aktiv-Dry LLC, and Professor,
Department of Chemistry and Biochemistry Center for Pharmaceutical Biotechnology, University of Colorado, Boulder
9.1.1 Aktiv-Dry’s PuffHaler
9.1.2 The Benefits of Inhaler Technology
9.1.3 The Competitive Landscape for Measles Inhaler Vaccines
9.1.4 ACTIV DRY’S Collaborations
9.1.5 The Challenges to Introduction Novel Inhaler Technology
9.2 Interview with David Hoey, CEO, Vaxxas
9.2.1 Vaxxas’s Nanopatch™ technology
9.2.2 The Advantages of Using Nanopatch Technology in Developed and Developing
Markets
9.2.3 The Challenges of Manufacturing Patch Technology
9.2.4 The Future for the Nanopatch Technology
9.3 Professor Mark Kendall, Inventor of the Nanopatch and Co-founder of Vaxxas
9.3.1 Microneedles: Proof of Concept to Commerical Product
9.3.2 Needle Delivery Market is Still Strong
9.3.3 The Microneedle Market
9.4 Interview with John Turanin, Vice President and General Manager, Zogenix Technologies
9.4.1 The Use of Gas Power in Jet Injectors
9.4.2 The Incentives for Drug Companies in Adopting Needle-Free Delivery
9.4.3 Regulating the Needle-Free Delivery Technology Market
9.4.4 Regional Market Forecasts for Jet Injectors
9.4.5 Jet Injectors: Competitive Space and Restraints on the Market
9.4.6 Regional Market Forecasts for Jet Injectors
9.4.7 Jet Injectors: Competitive Space and Restraints on the Market
9.5 Interview with Mark Logomasini, President and CEO, Bioject Medical Technologies
9.5.1 The Spring-Powered, Gas-Powered and Battery Powered Jet Injector Markets
9.5.2 Other Competing Needle-Free Delivery Platforms
9.5.3 Regulations Determine Jet Injector Market
9.5.4 Small Needle Free Delivery Companies Requires Large External Capital
10. Conclusions
10.1 The Needle-Free Delivery Market, 2014-2024
10.2 Transdermal Delivery For Vaccine Delivery
10.3 Biologic Drugs are a Major Driver of the Needle Free Delivery Market
10.4 Strong Pipeline Will Drive the Competing Needle-Free Injection Technology Market
10.5 Concluding Remarks


【レポート販売概要】

■ タイトル:ニードルフリー(無針)ドラッグデリバリー市場(2014-2024)
■ 英文:Needle-Free Delivery: Technology and Market Forecast 2014-2024
■ 発行日:2014年4月
■ 調査会社:visiongain
■ 商品コード:Visiongain-405312
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。